In a phase 3 non-inferiority trial of 564 women with high-intermediate risk endometrial cancer, molecular profile-based adjuvant treatment was non-inferior to vaginal brachytherapy for 5-year vaginal recurrence (4.5% vs 1.6%; HR 2.71), with 46% of the profile group only observed.
RCTn = 564
van den Heerik et al. Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial